Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta‐analysis
Authors' conclusion
Tirzepatide 10 and 15 mg once weekly significantly improve patient-reported physical function in adults with overweight or obesity. These findings suggest tirzepatide enhances perceived physical capacity and quality of life, although the extremely high between-study heterogeneity limits the interpretability of pooled estimates and warrants cautious interpretation.
Study context
- Population
- Adults with overweight or obesity; Randomized controlled trials (RCTs) reporting validated physical function outcomes (searched to July 20, 2025)
- Participants
- 4,531 adults6 RCTs
- Comparison
- Once-weekly tirzepatide 10 or 15 mg vs placebo
- Tirzepatiden = 2,802
- Outcome
- Change from baseline in SF-36 physical function domain and IWQOL-Lite-CT physical function subscale
Methodological detailsrandom-effects models
- Random-effects models
Pooled result
As reported in the abstract
Physical function (SF-36 and IWQOL-Lite-CT)
Tirzepatide vs PlaceboMD, points (95% CI)P value
SF-36 physical function; I2 = 99.8%
2.26(1.76–2.76)
P < 0.001IWQOL-Lite-CT physical function; I2 = 99.8%
10.10(8.61–11.60)
P < 0.001Further pooled results
Subgroup analyses by dose
- Consistent benefits for both 10 and 15 mg
Original publication
Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 18 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →